SANGAMO THERAPEUTICS, INC
SGMOQ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SGMOQ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SGMOQ
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for central nervous system disorders, with a cash runway limited to the third quarter of 2026 and a going concern qualification.
Key risk: Going concern risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates · 9 clinical trials for SANGAMO THERAPEUTICS, INC.
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for central nervous system disorders, with a cash runway limited to the third quarter of 2026 and a going concern qualification.
- Cash and equivalents of $27.6M as of 2026-03-31 [sec].
- Total revenue of $1.4M and net loss of -$31.0M for the quarter ended 2026-03-31 [sec].
- Management has expressed substantial doubt about the company's ability to continue as a going concern for at least the next 12 months [sec_mda · as of 2026-05-14].
- The company is actively seeking collaborations or transactions for its Fabry disease, hemophilia A, STAC-BBB capsid, and modular integrase platforms to extend cash runway beyond Q3 2026 [sec_mda · as of 2026-05-14].
- Preclinical programs focus on neurology disorders using a capsid engineering platform that has demonstrated expanded CNS delivery in preclinical studies [sec_mda · as of 2025-08-07].
What works
- The capsid engineering platform has shown ability to expand delivery beyond available intrathecal capsids in the CNS in preclinical studies [sec_mda · as of 2025-08-07].
- The company is actively pursuing partnerships for its Fabry disease, hemophilia A, STAC-BBB capsid, and modular integrase platforms, which could provide upfront funding [sec_mda · as of 2025-11-06].
- Sangamo has a portfolio of preclinical neurology programs that could address devastating CNS disorders if successfully developed [sec_mda · as of 2025-08-07].
What to weigh
- The company has a going concern qualification and expects cash to fund operations only through the third quarter of 2026 [sec_mda · as of 2026-05-14].
- Raising substantial additional capital is uncertain and may not be available on acceptable terms due to the speculative nature of reprioritized preclinical programs and lack of partners for advanced clinical programs [sec_mda · as of 2026-05-14].
- The company has not yet sought regulatory input for all potential therapeutic areas, and clinical trial costs could exceed hundreds of millions of dollars per product [sec_mda · as of 2026-05-14].
- Net loss of -$31.0M for the quarter ended 2026-03-31 with minimal revenue of $1.4M [sec].
From the filings
Quoted directly from source documents.
Cash runway limited to Q3 2026
“our ability to fund our current operations and to advance the development of our technologies and product candidates and to extend our cash resources beyond the third quarter of 2026 will remain wholly dependent on our ability to secure collaborations or other transactions”
SEC MD&A · May 14, 2026
Going concern qualification
“a going concern. We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in raising substantial additional capital”
SEC MD&A · May 14, 2026
Capsid platform CNS delivery
“our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies”
SEC MD&A · August 7, 2025
Seeking partners for Fabry, hemophilia A, STAC-BBB, modular integrase
“we are actively seeking commercialization and collaboration partners or a direct external investment, as applicable, to progress our Fabry disease and hemophilia A programs, STAC-BBB capsid and modular integrase platforms”
SEC MD&A · November 6, 2025
Catalyst timeline
- 2019-03-06 · Phase 1/2 study for Fabry disease (NCT03653247) completed — This study assessed safety and efficacy of a gene therapy candidate for Fabry disease; results may inform future development.
- 2019-07-23 · Phase 1/2 study for hemophilia A (NCT04046224) completed — This study evaluated safety and tolerability of a gene therapy candidate for hemophilia A; outcomes could influence partnership discussions.
- 2021-03-17 · Phase 1/2a study for another indication (NCT04817774) completed — This dose-ranging study assessed safety; data may support further clinical development.
- 2024-11-12 · Earnings report (SEC 8-K filing) — Financial results and business updates were disclosed; future filings will provide ongoing financial health indicators.
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has substantial doubt about ability to continue as a going concern for at least 12 months from filing date [sec_mda · as of 2026-05-14].
- Cash runway limited to Q3 2026 — Cash resources may not extend beyond Q3 2026 without new collaborations or transactions [sec_mda · as of 2026-05-14].
- Dependence on partnerships — Ability to fund operations depends on securing collaborations for advanced clinical programs, which may not materialize [sec_mda · as of 2026-05-14].
- High development costs — FDA approval process could cost hundreds of millions per product, and regulatory input has not been sought for all areas [sec_mda · as of 2026-05-14].
What to watch
- Ability to secure collaborations or transactions for Fabry disease, hemophilia A, STAC-BBB capsid, and modular integrase platforms before Q3 2026 [sec_mda · as of 2026-05-14].
- Progress of preclinical neurology programs and any regulatory feedback [sec_mda · as of 2025-08-07].
- Cash burn rate and any additional equity or debt financing [sec_mda · as of 2025-08-07].
- Updates on clinical trials for Fabry disease and hemophilia A programs [sec_mda · as of 2025-11-06].
Sources: Catalysts · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run SANGAMO THERAPEUTICS, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SANGAMO THERAPEUTICS, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.7 months
OCF -$19M · Net income -$31M
Lead: Approved
3 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
113
Total value held
$29.0M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 40,400,067 | $10.0M |
| vanguard capital management llc | 25,408,816 | $6.3M |
| two sigma investments, lp | 6,270,441 | $1.5M |
| balyasny asset management l.p. | 5,288,097 | $1.3M |
| geode capital management, llc | 4,570,862 | $1.1M |
| blackrock, inc. | 4,547,848 | $1.1M |
| renaissance technologies llc | 3,836,665 | $947K |
| susquehanna international group, llp | 2,752,363 | $683K |
| charles schwab investment management inc | 2,352,360 | $581K |
| vanguard fiduciary trust co | 2,310,297 | $571K |
Showing top 10 of 113 institutional holders of SANGAMO THERAPEUTICS, INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.4%
- Days to cover
- 5.5
- Shares short
- 42,883,635
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SGMOQ short interestGovernance
Frequently asked questions
What is the AI investment thesis for SANGAMO THERAPEUTICS, INC?
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for central nervous system disorders, with a cash runway limited to the third quarter of 2026 and a going concern qualification.
What is SANGAMO THERAPEUTICS, INC's lead drug candidate?
SANGAMO THERAPEUTICS, INC's most advanced tracked candidate is giroctocogene fitelparvovec (Approved) for moderately severe to severe hemophilia A.
Who is the CEO of SANGAMO THERAPEUTICS, INC?
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. is the chief executive officer of SANGAMO THERAPEUTICS, INC (SGMOQ).
Where is SANGAMO THERAPEUTICS, INC headquartered?
SANGAMO THERAPEUTICS, INC (SGMOQ) is headquartered in Richmond, CA, United States.
What therapeutic areas does SANGAMO THERAPEUTICS, INC focus on?
SANGAMO THERAPEUTICS, INC develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Cardiovascular, Infectious Disease, Pain, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.